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Abstract
Background: Endovenous thermal techniques, such as endovenous laser ablation (EVLA), are the recommended
treatment for truncal varicose veins. However, a disadvantage of thermal techniques is that it requires the
administration of tumescent anaesthesia, which can be uncomfortable. Non-thermal, non-tumescent techniques,
such as mechanochemical ablation (MOCA) have potential benefits. MOCA combines physical damage to
endothelium using a rotating wire, with the infusion of a liquid sclerosant. Preliminary experiences with MOCA
showed good results and less post-procedural pain.
Methods/Design: The Laser Ablation versus Mechanochemical Ablation (LAMA) trial is a single-centre randomised
controlled trial in which 140 patients will be randomly allocated to EVLA or MOCA. All patients with primary truncal
superficial venous insufficiency (SVI) who meet the eligibility criteria will be invited to participate in this trial. The
primary outcomes are intra-procedural pain and technical efficacy at 1 year, defined as complete occlusion of target
vein segment and assessed using duplex ultrasound. Secondary outcomes are post-procedural pain, analgesia use,
procedure time, clinical severity, generic and disease-specific quality of life, bruising, complications, satisfaction,
cosmesis, time taken to return to daily activities and/or work, and cost-effectiveness analysis following EVLA or MOCA.
Both groups will be evaluated on an intention-to-treat basis.
Discussion: The aim of the LAMA trial is to establish whether MOCA is superior to the current first-line
treatment, EVLA. The two main hypotheses are that MOCA may cause less initial pain and disability allowing
a more acceptable treatment with an enhanced recovery. The second hypothesis is that this may come at a
cost of decreased efficacy, which may lead to increased recurrence and affect longer term quality of life,
increasing the requirement for secondary procedures.
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Background
Varicose veins are a common disease worldwide, and in
the United Kingdom, it affects approximately one-third
of the population [1]. They are associated with symp-
toms causing pain and disability, soft tissue damage and
venous ulcer, resulting in significant quality of life im-
pairments [2] with consequent healthcare costs [3].
Endovenous thermal ablation (EVTA) techniques, such
as endovenous laser ablation (EVLA), are now widely ac-
cepted and they are recognised as the first-line treatment
for truncal varicose veins or superficial venous insuffi-
ciency (SVI) [4, 5]. This approach has been shown to
allow an enhanced recovery, with less pain and disability,
resulting in superior early quality of life (QoL) when
compared with surgical ligation and stripping, and im-
proved efficacy when compared with foam sclerotherapy
[6–11]. However, thermal ablation techniques carry the
risk of damaging perivenous soft tissue and/or nerves.
Thus, patients are treated with tumescent anaesthesia
(TA), which requires multiple injections in order to infil-
trate around the entire length of the target vein. Our
Public and Patient Involvement (PPI) group and patients
report that one of the major burdens associated with
endovenous thermal ablation is the discomfort during
injections of TA. Some patients still experience weeks of
post-procedural pain despite the use of TA [12].
Mechanochemical ablation (MOCA), using the ClariVein®
device (Vascular Insights, Madison, CT, United States) is a
newer treatment aiming to match the efficacy of thermal
ablation whilst using a gentle sclerotherapy technique, with
no requirement for TA. A catheter placed within the vein
deploys a rotating hollow wire which causes physical dam-
age to the endothelium and the vein goes into spasm. At
the same time, a sclerosing agent is injected through
the hollow wire into the vein, which results in protein
denaturation, endothelial destruction and endoluminal
fibrosis [13, 14]. Since no heat is involved and TA is
made redundant, thermal-related complications such as pain,
haematoma, induration and nerve injury could be reduced.
In the first human safety study, 30 great saphenous veins
(GSVs) with primary SVI in 29 patients were treated with
MOCA using sodium tetradecyl sulphate (STS) (Sotrade-
col). At 6 months [15] and at 2 years [16], the technical
efficacy was 97 % (29 of 30) and 96 % (27 of 28), respect-
ively. Several early case series have reported technical effi-
cacy, with occlusion rates varying from 87 to 97 % [17–20].
There were no serious adverse events such as pulmonary
embolism (PE), deep vein thrombosis (DVT) or nerve in-
jury observed in all previous studies. Furthermore, pro-
spective observational cohort studies suggest MOCA was
associated with significantly less procedure times, lower
post-procedural pain and faster recovery than endovenous
thermal ablation techniques [21, 22]. To date, no studies
have been performed to compare MOCA with EVLA in
the treatment of SVI. The current study has been designed
to compare MOCA with EVLA in the treatment of SVI in
a randomised controlled trial (RCT).
Methods/Design
Study objectives
The aim of this randomised clinical trial is to establish
whether MOCA is superior to the current first-line
treatment, such as EVLA. The two main hypotheses are
that MOCA may cause less initial pain and disability,
allowing a more acceptable treatment with an enhanced
recovery. The second hypothesis is that this may come
at a cost of decreased efficacy, which may lead to in-
creased recurrence and affect longer term quality of life,
increasing the requirement of secondary procedures.
Study design and setting
This is a phase IV randomised clinical trial in the set-
ting of a University Teaching Hospital, based in United
Kingdom, offering tertiary vascular surgery services.
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Inclusion criteria
The inclusion criteria are: aged 18 or over; primary
symptomatic SVI; reflux greater than 0.5 seconds in the
saphenous veins; clinical grades C2 to C6; proposed
treatment lengths of at least 10 cm; treatment with
either EVLA or MOCA is technically feasible; and writ-
ten informed consent.
Exclusion criteria
The exclusion criteria are: one of the treatments is
thought to be preferable by either the patient or an experi-
enced endovenous specialist; known allergy to medica-
tions or dressings used in the treatment; known right to
left circulatory shunt; evidence of acute deep vein throm-
bosis or complete ipsilateral occlusion; pelvic vein insuffi-
ciency; active or recent thrombophlebitis (within 6 weeks);
impalpable foot pulses with the Ankle Brachial Pressure
Index of less than 0.8; pregnancy or breast feeding; active
malignancy; immobility; involvement in other Clinical Tri-
als of an Investigational Medicinal Product (CTIMP)
within the last 6 months; and unwell or inability to comply
with the requirements for follow-up visits.
Treatment
All varicose vein procedures were carried out under
ultrasound guidance and local anaesthesia (LA) by vas-
cular surgeons who were experienced in both techniques
of endovenous ablation. No preoperative analgesia or
sedation is used. Initial vein access was performed under
ultrasound guidance after injection of local anaesthetic
(1 % lidocaine). With the patient in the reverse Trende-
lenburg position, the target vein will be cannulated per-
cutaneously under duplex ultrasound scan (DUS) at the
lowest point of demonstrable reflux using a 5-Fr sheath
and dilator, followed by a 0.018” guidewire. The total
length of truncal vein treated will be documented.
For EVLA, the dilator and guidewire will be exchanged
for a larger 0.035” wire using the Seldinger technique.
The treatment sheath is then introduced and its tip ac-
curately positioned at the saphenofemoral junction (SFJ)
or saphenopopliteal junction (SPJ) (as appropriate)
under DUS, aiming for a flush occlusion. The patient is
then put placed in the horizontal position, and perive-
nous tumescent anaesthesia (TA) is infiltrated around
the entire length of the target vein under DUS using a
spinal needle and a pedal-operated peristaltic pump. The
constituents of TA are 100 ml of 1 % lidocaine with
1:200,000 epinephrine in 900 ml of 0.9 % sodium
chloride, which is buffered to pH 7.4 with 10 ml of
8.4 % sodium bicarbonate. A sterile NeverTouch
Gold-Tip laser fibre is introduced and locks with the
treatment sheath. Endovenous laser energy is deliv-
ered using the VenaCure 1470 nm laser generator
(Angiodynamics, Waterlooville, UK) set at a continu-
ous power delivery of 10 W.
During MOCA, the ClariVein® catheter (Vascular
Insights, Glasgow, UK) will be inserted, aided by the
0.018” guidewire, and its tip is placed near the SFJ and
SPJ, as appropriate under DUS. The catheter is con-
nected to a 9 V battery-motorised handle unit that con-
trols wire rotation, and the patient is treated in a
horizontal position. The wire is activated for 10 seconds
in order to induce vasospasm, and the device is with-
drawn with a speed of approximately 7 seconds per
centimetre, while the sclerosant is continuously injected.
The sclerosing agent will be sodium tetradecyl sulphate
(STS), also known as STD injection and marketed as
Fibrovein 3 %, 1 %, 0.5 % and 0.2 % Solution for Injec-
tion (STD Pharmaceutical Products, Hereford, UK). The
concentration used will be 1.5 %, made from 2 ml am-
poule of 3 % STS with equal measures of 2 ml sterile
water (water for injection). Alternatively, diluting with
2 ml of 0.9 % normal saline is also satisfactory. The con-
centration and volume used will be clearly documented.
If required, concomitant ambulatory phlebectomy of
the varicose tributaries will then be performed using the
standard Oesch hook technique through 1–2 mm stab
incisions. The same TA will be infiltrated around any
tributaries to be treated. The phlebectomy sites will be
dressed with Steri-Strip™ (3 M, St Paul, MN, USA), cotton
wool, gauze and elastic compression dressings applied
from foot to knee or groin, as appropriate. This will be ex-
changed for a thigh-length anti-thromboembolism stock-
ing for 6 days after 24 hours. Patients will be advised to
immediately mobilise within their comfort level, and to re-
turn to their normal activities and work as soon as they
feel able to. Analgesia will not be routinely prescribed.
Primary outcomes
The joint primary outcomes will assess the hypothesised
advantages and disadvantages of MOCA when compared
with EVLA. The first will be patient-reported intra-
procedural pain measured on a standardised 100-mm
visual analogue scale (VAS). The second will be technical
efficacy at 1 year, with successful procedure defined as
complete occlusion of the target vein segment. This will
be assessed using duplex ultrasound.
Secondary outcomes
The secondary outcomes are procedure time, post-
procedural pain, analgesia use, clinical severity, generic
and disease-specific quality of life (QoL), bruising, com-
plications, satisfaction, cosmesis, time taken to return to
daily activities and/or work, and cost-effectiveness ana-
lysis following EVLA or MOCA.
The procedural time is from time of starting prepar-
ation to time of finishing dressing. Post-procedural pain
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will be recorded on a 100-mm VAS during the first
week after treatment. The type and daily dosage of any
analgesia taken by patients will also be recorded in a
diary for the first week. Bruising, satisfaction with treat-
ment and cosmesis will be recorded on a separate 100-
mm VAS.
Major complications include deep vein thrombosis,
pulmonary embolus, stroke, loss of vision, damage to
major artery, vein and/or motor nerve. Minor complica-
tions include superficial thrombophlebitis, numbness,
ecchymosis, persistent tenderness, lumpiness, skin stain-
ing and wound infection.
Disease-specific QoL is evaluated using the Aberdeen
Varicose Vein Questionnaire (AVVQ), the Chronic Venous
disease quality of life Questionnaire (CIVIQ-20) and the
VEnous INsufficiency Epidemiological and Economic
Study to evaluate Quality of Life and Symptoms (VEINES-
QOL/Sym). AVVQ is a validated instrument that reflects
the health status impairment associated specifically with
venous disease [23]. CIVIQ-20 was developed more re-
cently and it is designed to be more patient-centred [24].
VEINES-QOL/Sym is a 26-item patient-reported disease-
specific questionnaire to evaluate the QoL and symptoms
across the full spectrum of conditions related to chronic
venous disorders of the leg [25].
Generic QoL is assessed using the Short Form 36-item
(SF-36) and EuroQol 5-domain utility index (EQ5D).
The SF-36 is a multidimensional measurement of gen-
eral health, which yields eight domains of functional
health and well-being scores [26–28]. EQ5D is an index
scale mapping three available responses to five domain
questions [29], which is transformed using the UK time
trade-off tariffs into a global single index scale [30]. Both
have undergone extensive testing of validity and reliabil-
ity, including in the context of venous insufficiency and
treatment [31–33].
Two validated objective measures will be used to as-
sess and classify the severity of disease. The first is the
Clinical severity, Etiology, Anatomy and Pathophysiology
(CEAP) classification, which classifies severity into six
grades. The second is the Venous Clinical Severity Score
(VCSS), which grades three components from 0–3 with
increasing severity, and then summates them into a sin-
gle score. Clinical success is the objective improvement
of clinical outcome after treatment.
Post-procedural DUS will assess the treatment efficacy
[34]. Initial treatment success will be defined as complete
target vein occlusion at 1 and/or 6 weeks. Anything else
will be regarded as a technical failure. Recanalisation will
be assessed at 52 weeks and is defined as blood flow
within the target vein which has been treated. This will be
broken down into partial < 25 % or full ≥ 25 % of the
length of the treated vein. Residual disease is regarded as
any reflux which was also present at baseline, but not a
target for ablation. Disease progression will be defined as
any reflux within a vein which was not present on baseline
assessment. In the presence of clinical recurrence, DUS
will be used to map out the pattern of the recurrence as
this may give insight into techniques to avoid further re-
currence and aid understanding of how recurrence comes
about after these novel treatments. Post-procedural DUS
will also look for evidence of complications such as heat-
induced thrombosis, deep vein thrombosis, haematoma
and superficial thrombophlebitis.
Trial timescales
At the current rate of patients presenting to the unit, rela-
tively wide inclusion criteria and experience from previous
trials of this nature, it is anticipated that the recruitment
and treatment phase would be complete within approxi-
mately 18 months. The primary endpoint is measured at
1 year and therefore completion of data collection is antic-
ipated in approximately 30 months (Fig. 1).
Sample size calculation
The power calculation is based upon the joint primary
endpoints with 90 % power and 5 % significance. A pub-
lished comparison of MOCA and radiofrequency ther-
mal ablation found a reduction in intra-procedural pain
from 35 mm to 19 mm on a 100-mm visual analogue
scale (VAS) with a standard deviation of 20 mm [35].
This gives a required sample size of 33 patients per
group or 73 in the trial including 10 % loss to follow-up.
This difference is comparable with differences in
patient-reported pain VAS, which was previously found
to be associated with a difference in physical domains of
quality of life and associated with changes in recovery
time [8], and therefore can be judged to be clinically sig-
nificant. Previous comparisons of radiofrequency abla-
tion (RFA) with EVLA have suggested that EVLA is
associated with more post-procedural pain [12, 36–38].
However older laser delivery technology (bare-tip fibres),
shorter wavelength of laser (810–980 nm), additional
treatment to truncal varicose vein with the allocated
treatment at the same sitting, and general anaesthesia
(GA) were involved; thus their findings may not be ap-
plicable today. Furthermore, no study has shown any
significant benefit in quality of life relating to the re-
ported differences.
The same study [35] reported complete target vein oc-
clusion in 83 % of patients following MOCA at 1 month.
Our previous RCT found target vein occlusion in 99 % at
1 year following EVLA [7]. A difference of this magnitude
is likely to be clinically significant and have implications
towards the long-term durability of the procedure, affect-
ing effectiveness and cost-effectiveness. The required sam-
ple size to detect such a difference, if it exists, would be 62
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per group or 137 including 10 % loss to follow-up. Taking
this into consideration, the target sample size is 140.
Recruitment
Each patient referred to the vascular surgery services
with symptomatic SVI is assessed. Patients who poten-
tially meet the inclusion criteria will be made aware of
this research study and provided with the appropriate
information, including the Patient Information Sheet.
Patients expressing an interest in participation will be of-
fered an appointment for a screening visit with a study
investigator. At the screening appointment, the medical
history and examination will be reviewed, followed by
a detailed duplex ultrasound examination according
to a set protocol based upon international consensus
[39, 40]. If the potential participant meets the re-
quired inclusion criteria without any exclusion criteria,
subsequent discussion of the study will take place in full
(Fig. 1). If the potential participant meets the inclusion cri-
teria for the study and is willing and able to proceed to en-
rolment in the trial, they will then be consented using a
standardised Patient Consent Form. The Co-Investigators
and Principle Investigator will obtain informed consent.
Here the potential participant will be fully briefed on the
trial process, the treatments, follow-up, time commitments
and that this will be more detailed than regular follow-up
within the non-trial setting.
To ensure confidentiality and to adhere to the
Caldicott and Data Protection guidance, the partici-
pant will be assigned a unique study number for iden-
tification purposes; this will not allow identification of the
study arm or any demographic information. No informa-
tion identifying individuals including the study ID number
will be made available to anyone outside the research
group. A letter will be sent to the participant’s General
Practitioner to inform them of their enrolment into the
study and its details.
Randomisation
Consented participants will be allocated to one of the
two parallel treatments groups by equal randomisation
(Fig. 1), which will be conducted using an online compu-
terised service (Sealed Envelope, London, UK).
Blinding
Due to the nature of the procedures involved it will not
be possible to blind the participant or clinical team as to
which group the participant is allocated. Where possible,
assessor- reported outcomes will be performed by an in-
dependent assessor who is blinded to the treatment
Fig. 1 Study flow chart. The total target sample size is 140, which will be randomised to endovenous laser ablation (n = 70) or mechanochemical
ablation (n = 70)
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allocation. Bias in other outcomes will be limited by the
use of predetermined standardised objective measure-
ments, standardised protocols, and the extensive use of
patient-reported outcomes measures.
Data collection
Data for all outcomes from each participant’s visits will
be assimilated into the participants’ unique case report
form (CRF) and anonymised into a Microsoft Access
database to allow further analyses, and monitored by the
Research & Development (R&D) department.
Study visits
Baseline measurements will be collected from all partici-
pants once consent is obtained and prior to randomisa-
tion. Study measurements will be taken on the day of
treatment and on follow-up at 1 week, 6 weeks, 6 months
and 1 year. Clinical assessment, duplex ultrasound and
questionnaires are completed at these follow-up time
points (Table 1).
Statistical analysis
Results will be evaluated based on an intention-to-treat
analysis. Continuous data will first be tested for normal-
ity. Normally distributed data will be presented as mean
and standard deviation, and hypothesis testing per-
formed with paired and unpaired t tests, using two-sided
significance tests with a 5 % significance threshold. If the
data is not normally distributed, median and interquar-
tile range values will be presented, with analysis using
the Mann-Whitney U test for unrelated samples and
Wilcoxon signed rank test for paired data. Categorical
data will be analysed by means of X2 test or, if necessary,
Fisher’s exact test. Occlusion rates will be presented as
Kaplan-Meier curves, including censoring.
Monitoring, safety and quality control
This study will be monitored in accordance with the
Research & Development (R&D) Department’s standard
operating procedures to ensure compliance with the
International Conference on Harmonisation, Good
Clinical Practice and the Research Governance Frame-
work 2005.
Table 1 Schedule of assessments
Visits 1 2 3 4 5 6
Procedures Screening, eligibility, baseline
assessment and randomisation
Treatment 1-week follow-up 6-week follow-up 6-month follow-up 1-year follow-up
Medication history X X X X X X
Medications X X X X X X




CEAP X X X X X
VCSS X X X X X
AVVQ X X X X X
CIVIQ-20 X X X X X
VEINES-QOL/Sym X X X X X
SF-36 X X X X X
EQ5D X X X X X
DUS X X X X X
Pain VAS X X X X X
Analgesia diary X X X X X
Satisfaction VAS X X X X
Cosmesis VAS X X X X
Recovery time X X X X
Complications X X X X
NS-SEC National Statistics Socio-Economic Classification, CEAP Clinical severity, Etiology, Anatomy and Pathophysiology, VCSS Venous Clinical Severity Score, AVVQ
Aberdeen Varicose Vein Questionnaire, CIVIQ-20 Chronic Venous Insufficiency Questionnaire, VEINES-QOL/Sym VEnous INsufficiency Epidemiological and Economic
Study to evaluate Quality of Life and Symptoms, SF-36 Short Form 36-item, EQ5D EuroQol 5-domain utility index, DUS duplex ultrasound, VAS visual
analogue scale
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Adverse events (AE) are defined as any untoward med-
ical occurrence in a subject whom a medicinal product
has been administered, or a procedure performed, as part
of a research study, including occurrences which are not
necessarily caused by or related to that investigational me-
dicinal product (IMP). Serious adverse event (SAE) is any
event if it results in death, is life-threatening, requires hos-
pitalisation or prolongation of existing hospitalisation, re-
sults in significant or persisting disability or incapacity,
and is a congenital anomaly or birth defect. Adverse reac-
tion (AR) is any untoward or unintended response in a
subjection to an IMP. Serious adverse reaction (SAR) is a
serious event which is suspected (possibly, probably or
definitely) to be related to an IMP and expected for the
IMP. Suspected unexpected serious adverse reaction
(SUSAR) is a serious event which is suspected (possibly,
probably or definitely) to be related to an IMP and unex-
pected for the IMP, i.e. not previously documented in any
of the IMP information (SmPC) or protocol.
The AE reporting period for this trial begins as soon as
patients have consented to the trial and ends 30 days after
the patient’s treatment visit. The health status of subjects
will be checked at each study visit. The investigator will
record all directly observed AE and all AE spontaneously
reported by the trial subject. A pre-existing condition is a
disorder present prior to the patient entering the trial and
does not need to be reported as an AE unless the condi-
tion worsens or episodes increase in frequency during the
AE reporting period. All AE will be followed up by investi-
gators until the event has resolved or a decision has been
taken for no further follow-up. All AE (serious and non-
serious) will be recorded by the investigator in the case re-
port forms. A description of the event, including start date,
end date, action taken and the outcome will be provided.
Investigators will notify the R&D Department of any
SAE within 24 hours of becoming aware of the event. The
R&D Department will report fatal or life-threatening SUS-
ARs to the Medicines and Healthcare products Regulatory
Agency (MHRA) within 7 days and follow-up information
in a further 8 days. The R&D Department will send all
other SUSAR reports to the MHRA within a maximum of
15 days. The investigator will repot fatal or life-threatening
SUSARs to the Research Ethics Committee (REC) within
7 days and follow-up information within a further 8 days.
The investigator will send all other SUSAR reports to the
REC within a maximum of 15 days. The investigators will
submit a Development Safety Update Report (DSUR) to
the MHRA 12 months after the date of the MHRA clinical
trial authorisation and thereafter until the end of the study
according to the MHRA website.
Participants have access to information on complaints
procedure and for obtaining compensation and treatment
following harm through negligence or non-negligence as a
direct result of participating in the trial.
The end of trial is defined as the last visit of the last
subject completing their 1-year follow-up assessment. In
accordance with Trust policy all personal and/or sensi-
tive personal data (as defined by the Data Protection Act
1998) will be securely destroyed at the conclusion of the
research. Non-identifiable data and other records not
containing person-identifiable data may be retained for a
longer period at the discretion of the Principle Investiga-
tor. These will be stored appropriately to ensure its in-
tegrity, confidentiality and accessibility.
Discussion
Endovenous techniques have revolutionised the treatment
of truncal varicose veins, and endovenous thermal ablation
has become the recommended first-line treatment method
[4], achieving occlusion rates of greater than 90 % [11].
However, the search for the optimum treatment method is
still ongoing and recent emphasis has focused on improv-
ing outcomes such as intra- and post-procedural pain, and
reducing thermal-related injury and complications. A
potential solution to the problems raised by endovenous
thermal ablation is the use of newer non-thermal and non-
tumescent anaesthesia treatment methods such as MOCA.
The aim of the present randomised clinical trial is
twofold. The first hypothesis is that MOCA may cause
less initial pain and disability, allowing a more accept-
able treatment with an enhanced recovery. The second
hypothesis is that this may come at a cost of decreased
efficacy, which may lead to increased recurrence and
affect longer term QoL, increasing the requirement for
secondary procedures. In order to have sufficient power,
the trial was designed using a non-inferiority principle.
In conclusion, the LAMA trial is a randomised con-
trolled trial that aims for reduction in intra- and post-
procedural pain after MOCA compared with EVLA,
with a similar clinical success and technical efficacy.
Trial status
The LAMA trial began recruitment of participants in
June 2015. By the end of December 2015, 75 patients
had provided written informed consent and were subse-
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